Loading search results
MARS
A Cross-sectional Analysis of Musical Ability in Patients With Refractory Schizophrenia
Sponsor study identifier
observational
100
1 country
1
Study Start
June 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
The perception of music requires coordinated neural activities in distributed multi-functional centers across both hemispheres. The association between musical abilities and other general cognitive functions have been studied in several populations with inconsistent results. Schizophrenia is a major mental disorder that is strongly associated with cognitive deficits. These often appear before the onset of psychotic symptoms and persist throughout effective treatment of positive and negative symptoms. Like other disorders of psychosis, schizophrenia features general deficits in auditory memory and sensory processing. Recently, Sawada et al. (2014) and Wen et al. (2014) studied music abilities in Japanese and Chinese schizophrenic populations. They both used a standardized assessment for amusia called Montreal Battery of Evaluation of Amusia (MBEA) and found marked impairments in perception of scale, contour, interval, rhythm, meter and memory. Both studies showed that deficits in music perception were associated with cognitive deficits and negative symptoms. In regards to positive symptoms, Wen et al., but not Sawada et al., found a significant association. The present clinical study will assess musical abilities using the MBEA in a Canadian population with and without refractory psychosis. It will explore associations between musical deficits, positive and negative psychiatric symptomology and cognition. The patient population will have a diagnosis of schizophrenia, schizoaffective disorder, affective disorder with psychosis or non substance-related psychosis who were referred to the British Columbia Psychosis Program (BCPP) due to inadequate or no response to at least two trials of antipsychotics. A focus on refractory psychosis may provide greater insights because these patients have relatively more pronounced psychiatric symptoms and cognitive deficits. It will also be valuable to administer the MBEA assessment on a Canadian population, because the test was originally intended for Western populations and its musical phrases were designed with Western tonalities.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 28, 2015
Actual (reported)May 1, 2015
Actual (reported)June 2015
Date type not reportedThis date has not been verified as actual or estimated.
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Musical Ability (The Montreal Battery of Evaluation of Amusia)
Assessment of musical ability based on scores from The Montreal Battery of Evaluation of Amusia
2 hours
Cognitive Ability (NIH toolbox-cognitive battery scores)
1 hour
Mental Health Symptom Severity (Rating scales from Sci-PANSS and MINI Neuropsychiatric Interview)
2 hours
Participants without a psychosis disorder diagnosis.
Participants with a psychosis disorder diagnosis- recruited from the BC Psychosis Program.
There is no intervention associated with this study.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
The participant population will include all patients who have been admitted to the British Columbia Psychosis Progarm (BCPP) at the University of British Columbia (UBC) Hospital. Admission criteria to BCPP include the following: 1) Must be 18 years or older who are medically stable; 2) Diagnosis of schizophrenia, schizoaffective disorder, mood disorder with psychosis, or non-substance-related psychosis requiring diagnostic clarification; 3) History of no response or inadequate response of positive symptoms to at least 2 adequate trials of antipsychotics (one of which is a second generation agent) by health authority tertiary clinical teams; 4) Incomplete recovery of social, vocational, and occupational functioning likely to respond to active intervention. Control subjects will be age and gender matched with patient participants.
BC psychosis ward at UBC Hospital
Vancouver, British Columbia, Canada
Alasdair Barr, PhD
The University of British Columbia
First Submitted
April 28, 2015
First Posted
May 1, 2015
Study Start
June 2015
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2017
Estimated (date passed)Contact the study team to confirm eligibility.
This estimate has passed. The registry has not confirmed an actual date for this milestone.
Study Completion
May 2017
Estimated (date passed)This estimate has passed. The registry has not confirmed an actual date for this milestone.
Last Updated
May 25, 2016
Record last verified: 2016-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: